Document Detail


Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
MedLine Citation:
PMID:  19276256     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: This study was designed to evaluate the apoptotic effect of mapatumumab or lexatumumab, human agonistic antibodies that target the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2), in combination with chemotherapeutic agents, against human solid cancer cells. EXPERIMENTAL DESIGN: Cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Synergy was assessed by isobolographic analysis. RESULTS: Treatment of ACHN human renal cell carcinoma cells with cisplatin combined with mapatumumab did not overcome resistance to these agents. However, treatment with cisplatin in combination with lexatumumab had a synergistic cytotoxicity. Synergy was also achieved in six primary renal cell carcinoma cell cultures. Lexatumumab and cisplatin also synergistically enhanced apoptosis. Pretreatment with cisplatin followed by lexatumumab resulted in high cytotoxicity compared with the reverse sequence. Cisplatin significantly increased TRAIL-R2 expression at both the mRNA and the protein levels. Furthermore, the combination of lexatumumab and cisplatin significantly enhanced caspase-8 activity, Bid cleavage, up-regulation of Bax, cytochrome c release, and caspase-9, caspase-6, and caspase-3 activities. Importantly, the activation of caspase-8 was significantly abrogated by the specific inhibitors of caspase-9, caspase-6, and caspase-3. Furthermore, combination-induced cytotoxicity was significantly suppressed by the DR5:Fc chimeric protein and the specific inhibitors of caspase-8, caspase-9, caspase-6, and caspase-3. A similar effect was observed in prostate cancer, bladder cancer, lung cancer, and cervical cancer cells. CONCLUSIONS: Cisplatin sensitizes solid cancer cells to lexatumumab-induced apoptosis by potentiation of the extrinsic and intrinsic apoptotic pathways that lead to amplification of caspase activation, particularly caspase-8, suggesting the combination treatment of solid cancers with cisplatin and lexatumumab might overcome their resistance.
Authors:
Xiu-Xian Wu; Yoshiyuki Kakehi
Related Documents :
21480246 - Detection and prognostic impact of micrometastasis in colorectal cancer.
24329786 - Engineering t cells for cancer: our synthetic future.
24656976 - Her2 aberrations in cancer: implications for therapy.
25004306 - In vivo oocyte retrieval in a young woman with ovarian cancer.
10541986 - Nosocomial candidaemias due to species other than candida albicans in cancer patients. ...
22615136 - Progesterone and calcitriol attenuate inflammatory cytokines cxcl1 and -2 in ovarian an...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-03-10
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  15     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-03-17     Completed Date:  2009-04-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2039-47     Citation Subset:  IM    
Affiliation:
Authors' Affiliations: Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan; and Qiqiha Medical College, Heilongjiang, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / pharmacology*
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects*
Carcinoma, Renal Cell / drug therapy,  pathology
Caspases / physiology*
Cell Line, Tumor
Cisplatin / pharmacology*
Drug Synergism
Humans
Kidney Neoplasms / drug therapy,  pathology
Receptors, TNF-Related Apoptosis-Inducing Ligand / physiology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 0/lexatumumab; 15663-27-1/Cisplatin; EC 3.4.22.-/Caspases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cance...
Next Document:  Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malig...